| Filed On | Filing |
|---|---|
| 13 Nov 2026 | FORM 10-Q SEP 2026 |
| 02 Nov 2026 |
Form 4: Thomson Todd S, Director and 6 others
Granted 344,755 Warrants (right to buy) · Granted 355,245 Warrants (right to buy) |
| 30 Oct 2026 |
Form 4: Bios Fund III, Lp, Director and 2 others
Granted 3,000,000 Warrant (Right to Buy) |
| 30 Oct 2026 | SCHEDULE 13G |
| 30 Oct 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing. |
| 30 Oct 2026 |
Form 4: Bios Fund I, Lp, Director and 9 others
Granted 3,000,000 Warrant (Right to Buy) |
| 29 Oct 2026 |
Form 4: Schmitt Daniel M, Director
Bought 140,844 shares ($50K) · Acquired 70,422 Warrant to Purchase Common Stock (Open Market Purchase) |
| 28 Oct 2026 |
8-K: Entry into a Material Definitive Agreement; Other Events
The undersigned, Actuate Therapeutics, Inc., a corporation formed under the laws of the State of Delaware (collectively with its subsidiaries and affiliates, including, without limitation, all entities disclosed or described in the Regis... |
| 28 Oct 2026 | FORM 424B5 |
| 26 Oct 2026 | EFFECT |
| 19 Oct 2026 | FORM S-1 AMENDMENT |
| 14 Oct 2026 | FORM S-1 AMENDMENT |
| 08 Oct 2026 | FREE WRITING PROSPECTUS |
| 06 Oct 2026 | REGISTRATION STATEMENT |
| 14 Aug 2026 |
Form 4: Schmitt Daniel M, Director
Received 272,056 shares by exercise or conversion · Gave up 120,521 shares to cover exercise price or tax ($122K) |
| 14 Aug 2026 | FORM 10-Q FOR JUN 2026 |
| 17 Jul 2026 |
8-K: Notice of Delisting or Failure to Satisfy a Listing Rule
Notice of Delisting or Failure to Satisfy Continued Listing Rule or Standard; Transfer of Listing. |
| 08 Jun 2026 | DRS |
| 22 May 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On May 21, 2026, Actuate Therapeutics, Inc. (the “Company”) hosted its Annual Meeting of Stockholders (“Annual Meeting”) virtually. At the Annual Meeting, the Company's stockholders (i) elected each of the two Class II director nominees ... |
| 22 May 2026 |
Form 4: Zabrowski Dan, Director
Granted 15,000 Stock Options |
Loading...